Therapeutic optimism in the consent forms of phase 1 gene transfer trials: an empirical analysis

Background: “Therapeutic misconception” arises when human subjects interpret a clinical trial as aimed primarily at therapy rather than producing knowledge. Therapeutic misconceptions may be more prevalent in trials enrolling gravely ill subjects or involving novel and well publicised investigationa...

Full description

Saved in:  
Bibliographic Details
Authors: Kimmelman, J. (Author) ; Palmour, N. (Author)
Format: Electronic Article
Language:English
Check availability: HBZ Gateway
Journals Online & Print:
Drawer...
Fernleihe:Fernleihe für die Fachinformationsdienste
Published: BMJ Publ. 2005
In: Journal of medical ethics
Year: 2005, Volume: 31, Issue: 4, Pages: 209-214
Online Access: Volltext (JSTOR)
Volltext (kostenfrei)
Volltext (kostenfrei)

MARC

LEADER 00000naa a22000002 4500
001 1816128325
003 DE-627
005 20220908053410.0
007 cr uuu---uuuuu
008 220908s2005 xx |||||o 00| ||eng c
024 7 |a 10.1136/jme.2003.006247  |2 doi 
035 |a (DE-627)1816128325 
035 |a (DE-599)KXP1816128325 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 1  |2 ssgn 
100 1 |a Kimmelman, J.  |e VerfasserIn  |4 aut 
245 1 0 |a Therapeutic optimism in the consent forms of phase 1 gene transfer trials: an empirical analysis 
264 1 |c 2005 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
520 |a Background: “Therapeutic misconception” arises when human subjects interpret a clinical trial as aimed primarily at therapy rather than producing knowledge. Therapeutic misconceptions may be more prevalent in trials enrolling gravely ill subjects or involving novel and well publicised investigational agents. Objective: To examine the extent to which investigators express therapeutic optimism in phase 1 human gene transfer consent documents, whether highly active gene transfer researchers are more prone to expressing therapeutic optimism, and whether consent forms have grown more optimistic in their descriptions of personal benefit over the last decade. Design: Content analysis was performed on 277 consent documents to measure the number of sentences describing possibility of benefit, terminology used for experimental agents, the proportion of statements describing personal versus societal benefits, and whether investigators attempted to thwart therapeutic misconceptions. Results: Consent forms generally used therapeutic terminology to describe study agents, devoted more sentences to describing possible personal benefits than to describing benefits to society, and infrequently explained that a particular benefit was unlikely. Consent documents used by highly active gene transfer researchers tended to portray significantly greater optimism about personal benefit than less active investigators, though they were also significantly more cautious with agent terminology. Finally, therapeutic optimism expressed in consent forms has declined over the past decade. Conclusions: Consent documents used in phase 1 gene transfer trials, although increasingly attentive to possible therapeutic misconceptions, are inappropriately optimistic about direct benefits of trial participation. Such optimism is expressed more emphatically in trials involving highly active gene transfer researchers as principal investigators. 
601 |a Therapeut 
601 |a Transfer 
700 1 |a Palmour, N.  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Journal of medical ethics  |d London : BMJ Publ., 1975  |g 31(2005), 4, Seite 209-214  |h Online-Ressource  |w (DE-627)323607802  |w (DE-600)2026397-1  |w (DE-576)260773972  |x 1473-4257  |7 nnns 
773 1 8 |g volume:31  |g year:2005  |g number:4  |g pages:209-214 
856 |3 Volltext  |u http://www.jstor.org/stable/27719377  |x JSTOR 
856 |u https://europepmc.org/articles/pmc1734123?pdf=render  |x unpaywall  |z Vermutlich kostenfreier Zugang  |h repository [oa repository (via OAI-PMH doi match)] 
856 4 0 |u https://doi.org/10.1136/jme.2003.006247  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u http://jme.bmj.com/content/31/4/209.abstract  |x Verlag  |z kostenfrei  |3 Volltext 
935 |a mteo 
951 |a AR 
ELC |a 1 
ITA |a 1  |t 1 
LOK |0 000 xxxxxcx a22 zn 4500 
LOK |0 001 418558217X 
LOK |0 003 DE-627 
LOK |0 004 1816128325 
LOK |0 005 20220908053410 
LOK |0 008 220908||||||||||||||||ger||||||| 
LOK |0 035   |a (DE-Tue135)IxTheo#2022-08-02#75938EBC77997E72BADCE8BF4E17B6565BBC41BA 
LOK |0 040   |a DE-Tue135  |c DE-627  |d DE-Tue135 
LOK |0 092   |o n 
LOK |0 852   |a DE-Tue135 
LOK |0 852 1  |9 00 
LOK |0 866   |x JSTOR#http://www.jstor.org/stable/27719377 
LOK |0 935   |a ixzs  |a ixrk  |a zota 
OAS |a 1 
ORI |a SA-MARC-ixtheoa001.raw